Keegan 1991.

Methods	Six‐week randomised, double‐blind study
Participants	Outpatients fulfilling DSM‐III‐R or DIS criteria for unipolar major depression, with a score of at least 20 on the Hamilton Rating Scale for Depression‐21 item (HDRS‐21). Age range: 18‐70 years Exclusion criteria: any serious psychiatric disorder other than depression, such as schizophrenia, bipolar disorder, panic or obsessive disorder, alcohol or drug abuse within the past six months, serious medical disorders, use of psychoactive drugs that could affect mood.
Interventions	Fluoxetine: 20 participants Amitriptyline : 22 participants Fluoxetine dose range: 20‐80 mg/day Amitriptyline dose range: 100‐250 mg/day Only small amounts of benzodiazepines or chloral hydrate for sleep and anxiety were allowed
Outcomes	Diagnostic Interview Schedule, HDRS‐21, Beck Depression Inventory (BDI), Raskin Depression Scale (RDS), Covi Anxiety Scale (CAS)
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "study drugs were packaged as identical capsules"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Rating scale scores reported without denominators. Number and reasons for discontinuation reported
Selective reporting (reporting bias)	Unclear risk	Endpoint scores reported with standard deviations. Only 12 most common side effects reported
Other bias	High risk	Quote: "the study was supported by Eli Lilly, Canada Inc.". Eli Lilly Company produces fluoxetine